Pre-Open Movers 07/11: (AST) (VSAR) (SCYX) Higher; (VOXX) (IOTS) (ANGO) Lower (more...)

July 11, 2018 9:19 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Today's Pre-Open Movers

Asterias Biotherapeutics, Inc. (NYSE: AST) 22.6% HIGHER; announced that the Safety Review Committee (SRC) for the first clinical trial of AST-VAC2, held a scheduled meeting to review the safety and tolerability data generated in the first patient enrolled in the study and recommended continuation of the study and moving to parallel enrollment of the second and third patients in the advanced cancer cohort (Arm A), as planned per the studys protocol. This initial clinical trial, which is being sponsored, managed and funded by Cancer Research UK under a collaboration between Asterias and Cancer Research UK, will examine the safety and tolerability of AST-VAC2 in non-small cell lung cancer (NSCLC) as the studys primary endpoints. Secondary and tertiary endpoints of the study include evaluations of the immunogenicity of AST-VAC2 in NSCLC.

VOXX Int'l (NASDAQ: VOXX) 16.1% LOWER; reported Q1 EPS of ($0.04), $0.04 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $100.86 million versus the consensus estimate of $122.24 million.

Versartis Inc. (NASDAQ: VSAR) 12.2% HIGHER; Aravive Biologics, Inc. announced today that the company has completed both the single ascending dose and repeat dose portions of its Phase 1 study of AVB-S6-500 in healthy volunteers. The study met the safety and tolerability endpoints for the trial. As previously announced, the study also demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the study which demonstrated a dose-dependent decrease in measurable, circulating free GAS6 in serum. Aravive plans to submit full results of the study for potential presentation at a major medical meeting later in 2018. Also during the second half of 2018, the company expects to initiate the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500 with standard-of care-therapies in patients with platinum-resistant ovarian cancer.

Adesto Technologies (NASDAQ: IOTS) 10.3% LOWER; announced the pricing of an underwritten public offering of 6,700,000 shares of its common stock at a public offering price of $6.00 per share.

SCYNEXIS, Inc. (NASDAQ: SCYX) 9.7% HIGHER; announced positive results from its Phase 2b, dose-finding study (the DOVE study) evaluating oral SCY-078 for the treatment of vulvovaginal candidiasis (VVC). SCY-078, the first representative of a novel oral and intravenous triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including VVC, invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections.

AngioDynamics (NASDAQ: ANGO) 9.2% LOWER; reported Q4 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $88.3 million versus the consensus estimate of $89.32 million.

AAR Corp. (NYSE: AIR) 8.1% LOWER; reported Q4 EPS of $0.52, $0.01 better than the analyst estimate of $0.51. Revenue for the quarter came in at $474 million versus the consensus estimate of $483.51 million.

ArQule, Inc. (Nasdaq: ARQL) 7.5% LOWER; announced the pricing of an underwritten public offering of 11 million shares of its common stock at a price to the public of $5.50 per share.

Fastenal (NASDAQ: FAST) 6.7% HIGHER; reported Q2 EPS of $0.74, $0.08 better than the analyst estimate of $0.66. Revenue for the quarter came in at $1.27 million versus the consensus estimate of $1.26 billion.

Myriad Genetics (NASDAQ: MYGN) 4.4% HIGHER; Morgan Stanley upgraded from Equalweight to Overweight with a price target of $55.00 (from $35.00).

Saratoga Investment Corp. (NYSE: SAR) 3% LOWER; announced the commencement of a public offering of 1,000,000 shares of common stock.

Conn's Inc. (NASDAQ: CONN) 2.8% HIGHER; Stifel upgraded from Hold to Buy with a price target of $45.00 (from $35.00)

Sempra Energy (NYSE: SRE) 2.7% LOWER; announced that it is commencing concurrent offerings (the equity offerings) of $1.1 billion of shares of its common stock in connection with the forward sale agreements described below and $500 million of shares of its Mandatory Convertible Preferred Stock, Series B, each in a separate registered public offering, subject to market and other conditions.

TripAdvisor (NASDAQ: TRIP) 2.5% HIGHER; Barclays upgraded from Equalweight to Overweight with a price target of $70.00 (from $49.00).

WD-40 Co. (NASDAQ: WDFC) 2.3% LOWER; reported Q3 EPS of $1.15, $0.10 better than the analyst estimate of $1.05. Revenue for the quarter came in at $107 million versus the consensus estimate of $103.33 million. Board of Directors approves new 75.0 million share buyback plan to replace expiring plan. WD-40 Co. sees Q4 2018 EPS of $4.05-$4.10, versus the consensus of $4.09. WD-40 Co. sees Q4 2018 revenue of $403-411 million, versus the consensus of $408 million.

Simulations Plus (NASDAQ: SLP) 2% HIGHER; reported Q3 EPS of $0.13, in-line with the analyst estimate of $0.13. Revenue for the quarter came in at $8.6 million versus the consensus estimate of $8.09 million.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Stifel, Morgan Stanley, Barclays, Pre-Open Losers, Pre-Open Winners, Pre Market Movers